Literature DB >> 29754392

FTO, m6 Am , and the hypothesis of reversible epitranscriptomic mRNA modifications.

Jan Mauer1,2, Samie R Jaffrey2.   

Abstract

The fate of mRNA is regulated by epitranscriptomic nucleotide modifications, the most abundant of which is N6 -methyladenosine (m6 A). Although the pattern and distribution of m6 A in mRNA is mediated by specific methyltransferases, a recent hypothesis is that specific demethylases or 'erasers' allow m6 A to be dynamically reversed by signaling pathways. In this Review, we discuss the data in support and against this model. New insights into the function of fat mass and obesity-associated protein (FTO), the original enzyme thought to be an m6 A eraser, reveal that its physiologic target is not m6 A, but instead is N6 ,2'-O-dimethyladenosine (m6 Am ). Another m6 A demethylase, ALKBH5, appears to have functions limited to sperm development in normal mice. Overall, the majority of the data suggest that m6 A is generally not reversible, although m6 A may be susceptible to demethylation in pathophysiological states such as cancer.
© 2018 Federation of European Biochemical Societies.

Entities:  

Keywords:  ALKBH5; N6,2′-O-dimethyladenosine; N6-methyladenosine; RNA modifications; epitranscriptome; fat mass and obesity

Mesh:

Substances:

Year:  2018        PMID: 29754392     DOI: 10.1002/1873-3468.13092

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  28 in total

Review 1.  Small changes, big implications: The impact of m6A RNA methylation on gene expression in pluripotency and development.

Authors:  Adam M Heck; Carol J Wilusz
Journal:  Biochim Biophys Acta Gene Regul Mech       Date:  2019-07-17       Impact factor: 4.490

Review 2.  Epitranscriptomic regulation by m6A RNA methylation in brain development and diseases.

Authors:  Anil K Chokkalla; Suresh L Mehta; Raghu Vemuganti
Journal:  J Cereb Blood Flow Metab       Date:  2020-09-23       Impact factor: 6.200

3.  The dynamics of FTO binding and demethylation from the m6A motifs.

Authors:  Yixing Li; Kejing Wu; Weili Quan; Lin Yu; Shuang Chen; Chao Cheng; Qijia Wu; Shuhong Zhao; Yi Zhang; Lei Zhou
Journal:  RNA Biol       Date:  2019-05-31       Impact factor: 4.652

Review 4.  Novel positioning from obesity to cancer: FTO, an m6A RNA demethylase, regulates tumour progression.

Authors:  JiaLing Chen; Bin Du
Journal:  J Cancer Res Clin Oncol       Date:  2018-11-21       Impact factor: 4.553

Review 5.  The epitranscriptome beyond m6A.

Authors:  David Wiener; Schraga Schwartz
Journal:  Nat Rev Genet       Date:  2020-11-13       Impact factor: 53.242

Review 6.  Nucleoside analogs in the study of the epitranscriptome.

Authors:  Cody M Palumbo; Peter A Beal
Journal:  Methods       Date:  2018-10-26       Impact factor: 3.608

7.  Altered m6A Modification of Specific Cellular Transcripts Affects Flaviviridae Infection.

Authors:  Nandan S Gokhale; Alexa B R McIntyre; Melissa D Mattocks; Christopher L Holley; Helen M Lazear; Christopher E Mason; Stacy M Horner
Journal:  Mol Cell       Date:  2019-12-03       Impact factor: 17.970

8.  Effect of Posttranslational Modifications on the Structure and Activity of FTO Demethylase.

Authors:  Michał Marcinkowski; Tomaš Pilžys; Damian Garbicz; Jan Piwowarski; Damian Mielecki; Grzegorz Nowaczyk; Michał Taube; Maciej Gielnik; Maciej Kozak; Maria Winiewska-Szajewska; Ewa Szołajska; Janusz Dębski; Agnieszka M Maciejewska; Kaja Przygońska; Karolina Ferenc; Elżbieta Grzesiuk; Jarosław Poznański
Journal:  Int J Mol Sci       Date:  2021-04-26       Impact factor: 5.923

Review 9.  Regulatory Mechanisms of the RNA Modification m6A and Significance in Brain Function in Health and Disease.

Authors:  Justine Mathoux; David C Henshall; Gary P Brennan
Journal:  Front Cell Neurosci       Date:  2021-05-19       Impact factor: 5.505

Review 10.  From A to m6A: The Emerging Viral Epitranscriptome.

Authors:  Belinda Baquero-Perez; Daryl Geers; Juana Díez
Journal:  Viruses       Date:  2021-06-01       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.